As shown, the sialylation of the EGFR affects EGFR-mediated cell growth and reduces sensitivity to gefitinib in human colon cancer cells, whereas the anticancer effect of gefitinib was augmented in ST6Gal-1-deficient cells [125]. This evidence concerns the gene ST6GAL1 and malignant colon neoplasm.